ANCA-associated Vasculitis Clinical Trials

20 recruitingLast updated: June 18, 2026

There are 20 actively recruiting anca-associated vasculitis clinical trials across 7 countries. Studies span Early Phase 1, Not Applicable, Phase 1, Phase 2, Phase 4, Phase 3. Top locations include Brest, France, Nantes, France, Angers, France. Updated daily from ClinicalTrials.gov.


ANCA-associated Vasculitis Trials at a Glance

20 actively recruiting trials for anca-associated vasculitis are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Early Phase 1 with 3 trials, with the heaviest enrollment activity in Brest, Nantes, and Angers. Lead sponsors running anca-associated vasculitis studies include Assistance Publique - Hôpitaux de Paris, Chinese SLE Treatment And Research Group, and Nanjing Bioheng Biotech Co., Ltd..

Browse anca-associated vasculitis trials by phase

Treatments under study

About ANCA-associated Vasculitis Clinical Trials

Looking for clinical trials for ANCA-associated Vasculitis? There are currently 19 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new ANCA-associated Vasculitis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about ANCA-associated Vasculitis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 20 trials

Recruiting

Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis

ANCA-associated VasculitisGiant Cell ArteritisTakayasu's Arteritis+2 more
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)4,000 enrolled1 locationNCT02257866
Recruiting

EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases

PericarditisRheumatoid ArthritisSarcoidosis+10 more
Assistance Publique - Hôpitaux de Paris5,000 enrolled1 locationNCT07077304
Recruiting
Early Phase 1

Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases

Sjogren's SyndromeAutoimmune DiseasesIdiopathic Inflammatory Myopathies+3 more
Nanjing Bioheng Biotech Co., Ltd.20 enrolled1 locationNCT06548607
Recruiting
Early Phase 1

A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases

IgA Nephropathy (IgAN)Membranous NephropathyANCA-associated Vasculitis (AAV)/ANCA-associated Glomerulonephritis (AAGN)+2 more
Grit Biotechnology30 enrolled1 locationNCT07389499
Recruiting

(68)Ga-FAPI PET/CT in Patients With ANCA-associated Vasculitis

ANCA-associated Vasculitis
Ruijin Hospital30 enrolled1 locationNCT07151521
Recruiting
Early Phase 1

A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.

SLEANCA-associated VasculitisIIM+5 more
Nanjing Bioheng Biotech Co., Ltd.84 enrolled1 locationNCT07203404
Recruiting
Phase 1

The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases

ANCA-associated VasculitisIgG4-Related DiseasesLupus Nephritis+1 more
Nanjing University School of Medicine24 enrolled1 locationNCT06285279
Recruiting
Phase 3

A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial

ANCA-associated VasculitisCrescentic GlomerulonephritisRapidly Progressive Glomerulonephritis
Assistance Publique - Hôpitaux de Paris126 enrolled24 locationsNCT05946564
Recruiting
Phase 1Phase 2

Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases

DermatomyositisPolymyositisANCA-associated Vasculitis+2 more
Fondazione Policlinico Universitario Agostino Gemelli IRCCS8 enrolled1 locationNCT06685042
Recruiting
Phase 2

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

Systemic Lupus ErythematosusSjogren SyndromeInflammatory Myopathy+6 more
Peking University People's Hospital50 enrolled1 locationNCT06794008
Recruiting

PRediction of DIverse Glucocorticoids ToxIcity OUtcomeS

Idiopathic Inflammatory MyopathiesANCA-associated VasculitisGiant Cell Arteritis+3 more
University Hospital, Brest300 enrolled11 locationsNCT04664465
Recruiting

Avacostar - (PASS)

ANCA-associated Vasculitis
Vifor Fresenius Medical Care Renal Pharma500 enrolled35 locationsNCT05897684
Recruiting

Early-access Avacopan in Real-world ANCA-associated Vasculitis

ANCA-associated Vasculitis
Leiden University Medical Center100 enrolled1 locationNCT06794827
Recruiting

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Refractory AAV

CAR-T Cell TherapyANCA-associated Vasculitis
The Children's Hospital of Zhejiang University School of Medicine12 enrolled1 locationNCT06508346
Recruiting
Not Applicable

Biocollection of Patients With ANCA Associated Vasculitis

ANCA-associated Vasculitis
University Hospital, Brest100 enrolled1 locationNCT05364892
Recruiting

Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis

Systemic Lupus ErythematosusDermatomyositisSystemic Sclerosis+2 more
CHU de Reims260 enrolled1 locationNCT06462768
Recruiting
Not Applicable

Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells

ANCA-associated VasculitisLupus Nephritis
Lingli Dong24 enrolled1 locationNCT06277427
Recruiting
Phase 4

Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)

Maintenance TherapyANCA-associated Vasculitis
Chinese SLE Treatment And Research Group40 enrolled1 locationNCT05965284
Recruiting
Phase 4

Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)

ANCA-associated Vasculitis
Chinese SLE Treatment And Research Group40 enrolled1 locationNCT05962840
Recruiting

Multicenter Cohort Study of AAV in Hunan of China

ANCA-associated Vasculitis
Xiangya Hospital of Central South University500 enrolled1 locationNCT05315141